Supplementary Table 1. Triplicate samples of clenbuterol treated and saline treated controls from each of the days 1 and 28 day groups were analyzed using Affymetrix DNA oligonucleotide RAE230 2.0 microchips (Affymetrix  Santa Clara  CA  USA) and data analyzed using the Genespring software suite (Agilent  Santa Clara  CA  USA) as described. Lists of genes altered in response to 1 or 28 days of clenbuterol treatment are listed; genes up-regulated at 1 day (Up clen 1d)

Supplementary Table 3. Triplicate samples of clenbuterol treated and saline treated controls from each of the days 1 and 28 day groups were analyzed using Affymetrix DNA oligonucleotide RAE230 2.0 microchips (Affymetrix  Santa Clara  CA  USA) and data analyzed using the Genespring software suite (Agilent  Santa Clara  CA  USA) as described. Lists of genes altered in response to 1 or 28 days of clenbuterol treatment are listed; genes up-regulated at 28 days (Up clen 28 d)

Supplementary Table 4. Triplicate samples of clenbuterol treated and saline treated controls from each of the days 1 and 28 day groups were analyzed using Affymetrix DNA oligonucleotide RAE230 2.0 microchips (Affymetrix  Santa Clara  CA  USA) and data analyzed using the Genespring software suite (Agilent  Santa Clara  CA  USA) as described. Lists of genes altered in response to 1 or 28 days of clenbuterol treatment are listed; genes down-regulated at 28 days (Down clen 28 d respectively)

Table 4. PK Genes Specifically Expressed in B-NEG Patients Versus at Least 2 Other Groups

Table 3. PK Genes Distinctive of Each ALL Subgroup

Table 2. Probes with significantly different expression between patients with and without liver metastasis by GeneChip analysis and their validation results with TaqMan real-time PCR.

Table 2. Downregulated genes in lymph node metastasis compared with primary gastric carcinoma

Table 1. Upregulated genes in lymph node metastasis compared with primary gastric carcinoma

SuppTable 2. GO analysis of significantly differentially expressed probesets in the t-tests according to histological grade (a) and number of CGH imbalances (b).